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Abstract: Hepatitis C virus is a life threatening viral infection of the liver, while co-infection with human 
immunodeficiency virus (HIV) is a growing public health concern. The study was conducted among confirmed HIV 
infected patients attending the Talata - Mafara General Hospital. One hundred and Ninety two (192) serum samples 
were assayed for the presence of antibodies to HCV, using a third generation enzyme linked immunsorbent assay. A 
well-structured questionnaire was administered to volunteer subjects after consent approval to obtain demographic 
and other relevant Data. Overall result showed that 37(19.3%) of the subjects screened had antibodies to HCV, the 
prevalence of HCV was higher among males subjects with 25(13%) positivity compared to the females subjects with 
12 (6.3%). Considering prevalence based on age, individuals of the age group 21-30 and 31-40 recorded a higher 
prevalence of 7(2.6%) and 10(5.2%) respectively. Based on marital status a high prevalence of 14(7.2%) was 
recorded among widows and widowers. Educational status showed that subjects with secondary education recorded 
a prevalence of 12(6.2%) positivity. From this study it is paramount that adequate diagnosis of the Hepatitis C Virus 
be carried out in people with HIV infection so as to reduce further complications among co-infectious subjects in the 
population.  
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1. Introduction:  
Human Immunodeficiency Virus (HIV) is a 
major public health concern and cause of death in 
Africa. Although Africa is inhabited by over 14.7% of 
the world’s population, it is estimated to have more 
than 88% of people living with HIV and 92% of all 
AIDS death in 2007 (UNAIDS, 2008). Life 
expectancy of patients with HIV has increased and 
focus has now shifted to the management of 
concurrent illness such as chronic HCV infection and 
other co-infections which have the potential to 
increase long term morbidity and mortality (Munshi et 
al., 2008). Hepatitis C virus (HCV) is an RNA virus 
with envelope, a single stranded, of positive sense that 
belongs to the family flaviviridae (Lauer and Walker, 
2001). It is RNA dependent, RNA polymerase, small 
measuring between 30-60nm in diameter. 170 million 
people (about 3%) of global population are 
chronically infected with HCV, and most of these 
cases occur in Africa with the highest prevalence 
(WHO, 2004). HCV strains exhibit considerable 
variation in genomic structure. Hepatitis C virus 
(HCV) is mounting a global health challenge, causing 
a significant proportion of chronic liver disease 
around the world. In understanding the long term 
outcomes of HCV infection among HIV patients, 
clinicians may need to identify the patients at risk for 
HCV-related complication and offer treatment to 
prevent further morbidity and mortality, (Choo et al., 
1989). Chronic hepatitis C is the most common cause 
of chronic liver disease and cirrhosis, and the most 
common indication for liver transplantation in the 
United State, Australia, and most of Europe (Wasley 
and Alter, 2000). About 60-70% of patients with acute 
HCV infection may progress to chronic infection. 
Similarly, Infection with HIV leads to a progressive 
distribution in the number of T-cells possessing CD4+ 
receptors (Ryu et al., 1994). Progressive depletion of 
CD4+ T-cell lymphocytes is the cardinal events in the 
pathogenesis of infection by the HIV-1. Enumeration 
of CD4+ lymphocytes may aid in the diagnosis or 
prognosis of immunodeficiency as AIDS. Not only is 
the CD4+ T-cells enumeration important in 
classification of disease severity, it is equally 
important is assessment of response to HAART 
(Akanmu et al., 2003, Awalu and Chukwedo, 2008). 
The lower the CD4+ count (normal counts are usually 
between 500cell/µl – 1600 cells/µl), the greater the 
likely damage of HIV to such individuals (CDC, 
2008). It has also been discovered than Hepatitis C 
Virus, which shares a common mode of transmission 
is prevalent in HIV positive individuals,(Santiago, 
2005). 
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2.Materials And Methods 
Study area 
The project was carried out amongst HIV – 
infected individuals whose CD4+ count were 
determined when they are confirmed HIV-positive at 
General Hospital Talata-Mafara in Zamfara State.The 
work was carried out between July – September, 2010. 
Subjects 
Confirmed HIV patients attending (GHAIN) 
laboratory in General Hospital Talata Mafara within 
the locality. 
Sample Size 
A total of 192 seropositive HIV patient attending 
General Hospital Talata Mafara, Zamfara state within 
the age bracket of 11-60years. 
Questionnaire 
Structural questionnaire comprising of subjects 
information on their biodata e.g. sex, age, marital 
status, family history on HCV were administered 
simultaneously to the subjects so as to know their 
demographic data in the analysis of the results 
obtained. 
Ethical Clearance 
Ethical clearance was sought for and obtained 
from the Hospital Talata Mafara management through 
the chairman, ethical clearance committee. 
Specimen Collection and Storage 
4mls use whole blood specimen collected by 
venipuncture in evacuated blood collection K2EDTA 
or K3EDTA containers. Samples that are not 
immediately used should be stored at 18-220C but the 
test should be performed within 48hours but no later 
than 72 hours after the blood specimen (kept at room 
temperature) is drawn. The CD4+ count of 190 blood 
specimen of HIV – infected persons were estimated 
and monitored after period of 3 months using the 
facscount machine. 
Scope of Study 
They CD4+ count of 192 blood specimen of 
confirmed HIV-infected person undergoing HAART; 
highly active antiretroviral therapy and suspected 
hepatitis C case of those infected patients were 
estimated and monitored after a period of 3months 
using the facscount and 3rd generation enzymes – 
linked immune sorbent assay for testing of hepatitis C 
virus. 
Principle of enzyme immunoassay 
Multiple epitopes of HCV proteins are bound to 
the microtitre wells. When antibodies to HCV are 
present in the test sample, they react with recombinant 
proteins and attach to the solid phase. No reactive 
antibodies are removed with the wash buffer. Human 
lgGs bound to the antigen are reacted with goat – anti 
– human lgG peroxidase conjugate and visualized by 
subsequent reactions with a chromogenic substrate. 
Positive sample generates a medium to dark blue 
colour. No colour or very pale blue colour indicates a 
negative reaction. The intensity of the reaction is 
photometrically quantities. 
Specimen Collection and Preparation for sreening: 
Serum should be prepared from a whole blood 
specimen obtained by acceptable medical techniques. 
Either serum plasma can be used in this test. Remove 
serum or plasma from the clot or blood cells as soon 
as possible to avoid haemolysis. Specimen with 
extensive particulate should be clarified by 
centrifugation prior to use. Specimen frozen at 200C or 
colder may be used. Avoid repeated freeze thaw. 
3. Result 
192 samples were screened and confirmed 
seropositive and their CD4 lymphocyte count were 
estimated. From the result 115 female patients tested 
positive, while about 75male patient were reactive to 
the test (HIV seropositive). 
Among the 192 HIV positive subjects 37(67.5%) 
tested positive for HCV antibodies with 29 males and 
12 (32.4%) females, as seen in Table1. 
Table 2 showed distribution based on sex ,a 
higher rate of infection were recorded among male 
subject aged 31-40, with 5.6% prevalence while 
females aged 21-30 recorded 2.6 positivity. 
Table 3 showed distribution of HCV based on 
marital status with the high prevalence rate of 7.2% in 
males, while the females recoded (0%) rate. 
 
Table 1: Overall Sample Distribution Of Patients 
Based On Sex 






Male 77(40.1%) 25 13.0 
Female 115(59.8%) 12 6.3 
Total 192(99.9%) 37 19.3 
 
Table 2: Age Distribution Of Hcv Positive Subjects 
Age (Years) Male Female Total 
11-20 (0%) 1(0.5%( 1(0.5%) 
21-30 5(2.6%) 7(3.6%) 12(6.2%) 
31-40 10(5.2%) 2(1.0%) 12(6.2%) 
41-50 8(4.1%) 2(1.0%) 10(5.1%) 
51-60 2(1.0%) –(0%) 2(1%) 
Total 25(12.9%)     12(6.1%) 37(19%) 
 
Table 3: Distribution Of Hcv Positivity Based On 
Marital Status 
Marital status Male Female total 
    
Monogamy 6(3.1%) 8(4.1%) 14(7.2%) 
Polygamy 3(1.5%) 3(1.5%) 6(3.1%) 
Widow/widower 14(7.2%) 0(0%) 14(7.2%) 
Divorce 1(0.5%) 1(0.5%) 2(1%) 
Single 1(0.5%) (0%) 1(0.5%) 
Total 25(12.8%) 12(6.1%) 37(19%) 




Table 4: Distribution Of Hcv Based On 
Educational Status Of Positive Patients 
Educational 
status 
Male Female Total 
Non-Formal 
Education 
(0%) 2(1.0%) 4(1.0%) 
Primary 
Education 
10(5.2%) 2(1.0%) 12(6.2%) 
Secondary 
Education 
12(6.25%) 8(4.1%) 20(10.3%) 
Tertiary 
Education 
3(1.5%) (0%) 3(1.5%) 
Total 25(12.9%) 12(6.1%) 37(19%) 
 
Table 4 which was based on Educational status 
shows its highest rate of 6.25% with those having 
secondary Education, while it is 0% in females. 
 
4. Discussion 
Anti-retroviral drugs has transformed HIV/AIDS 
from a uniformly fatal illness into a manageable 
chronic infection and has been shown to be able to 
restore CD4 + cells in HIV infected patients (Rathbun 
et al., 2006). The gains of HAART could be 
compromised by co-infection with hepatitis viruses as 
they are known to have adverse effects on the 
prognosis of HIV and hepatitis infections (Feld et al., 
2005) consequently increased attention has to be paid 
on co-infection of hepatitis viruses and HIV especially 
in the developing countries like Nigeria  where these 
groups of viruses are endemic. In this study out of the 
number of patient screened (39.0%) were male with 
HIV positive status while (59.8%) were positive for 
female. It shows that there is a higher prevalence of 
infection in the female folk compared to the male  in 
Zamfara State which could be as a result of mass 
illiteracy among the females , early marriage, and 
polygamous lifestyle , which encourage the spread of 
the virus. The study also reveals HCV seroprevalence 
rates of (19.3%) in group of HIV – 1 infected 
individuals samples, with a (13.0%) HCV positivity 
for the male and (6.3%) for female, which is similar to 
the study comes carried out in Jos  by Alabi et 
al.,2007),who recorded 11.1% seropositivity among 
the subjects. 
Previous studies in Nigeria has reported an 
overall HCV prevalence of (2.9%) among  blood 
donors in Rivers State of Nigeria (Kaote et al., 2005), 
(Agwale et al., 2004) also recorded an HCV 
seroprevalence  of 8.2%  among HIV infected 
Nigerians. There is a clear indication of increased 
HCV infection in HIV infected individuals in Nigeria. 
It is known that HIV/HCV co-infected individuals 
accelerate rapidly to end – stage liver disease, AIDS 
defining clinical event and death (Greub, 2000, Manga 
et al., 2001). 
In Table 2 Age distribution of HCV positive 
subjects shows a marked prevalence among subject 
aged 31-40 in males (5.2%) compared to the female 
(3.6%) of age group 21-30. In our location of study it 
was observed that the male subject   in this study 
inclined to drug abuse such as IVDU from the use of 
syringes, sharing of infected instrument like razor, 
clipping of nails with unsterilized manicure 
instruments, while is a propable  avenue for the spread 
of the virus as transmission involves blood contact. 
Table 3 showed distribution of HCV positive 
individuals based on marital status with a high 
prevalence rate of HCV among the widow/widower, 
having (7.2%) prevalence, there is no significant rate 
with the divorce and single group with a (0.5%) and 
(0%) respectively, however the monogamous and 
polygamous group both have (3.1%) for the males and 
(4.1%) for the females. 
Table 4, shows prevalence rate distribution based 
on educational status with a high rate of infectivity 
recorded among those with Secondary Education for 
the male subjects with  (6.25.% )positivity compared 
to the females with (4.1%). The result obtained in this 
study based on educational distribution; is similar to 
the work of (Kuo et al., 2006) where it was observed 
that despite the high HCV prevalence less than 50% 
had any formal education, out of these less than 20% 
was aware of HCV, which underscore the need for 
expanded education and public enlightenment on the 
hepatitis C virus. While HIV and HCV educational 
prevention programmes be focused to reduce the 
stigma HIV and HCV co-infection of those having 
secondary education. The average CD4 count for the 
female shows (279 cell/µ) compared to the male of 
(1509 cell/µ). Infection with HIV/HCV has been 
reported to have therapy (Ranieri et al., 2002) as a 
case seen a 35years old female client co-infected with 
HIV and HCV who virologically failed therapy (CD+ 
decline from 199 to 66) after four months of HAART, 
there is also records that, the rate of increase in CD4+ 
cells post – HAART does not change in HIV and 
hepatitis co-infection. Although there have been a case 
reports of clearance of HCV viraemia after initiation 
of HAART (Ranieri et al., 2002), majority of 
available data indicates that HAART results net 
increase in HCV viraemia (Change et al., 2002). 
Triple coinfected individuals i.e. HIV/HRV/HCV are 
more likely to present with lower CD4+ counts and 
therefore reduced host immunity. Triple co-infection 
is therefore a growing problem in Nigeria and needs 
careful attention owing to its adverse effects on HIV 
treatment response, unfortunately however, no 
effective vaccines has been developed against HCV 
infection. The study therefore confirms the endemicity 
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Based on the analysis and result obtained it is 
recommended that, upon confirmation of HIV 
infection, all patients should also be tested for HCV 
infection while CD4+ FACS counting facility be 
employed to enable easy determination of patient 
CD4+ count. Combined therapeutic regimen should be 
administered to individuals co-infected with HIV and 
HCV immediately to avert further complications. 
Importantly free voluntary testing at no cost should be 
made available and accessible to patient who wishes 
to know their HCV status. 
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